Toggle Main Menu Toggle Search

Open Access padlockePrints

An international survey on patterns of practice in NAFLD and expectations for therapies—The POP-NEXT project

Lookup NU author(s): Professor Quentin AnsteeORCiD

Downloads


Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by John Wiley and Sons Inc., 2022.

For re-use rights please refer to the publisher's terms and conditions.


Abstract

© 2022 American Association for the Study of Liver Diseases. Background and Aims: Differences between countries in NAFLD patient care pathways and management need to be understood prior to defining supranational guidelines. Approach and Results: We conducted an anonymous survey in France, Germany, Hong Kong, Italy, Romania, Spain, the United Kingdom, and the United States among physicians providing specialist care for patients with NAFLD. Modalities of patient referral, patterns of practice (diagnosis, staging, monitoring, and indications for liver biopsy), therapeutic management, and expectations for future NASH pharmacotherapies were assessed, with 664 physicians completing the survey. Referral to surveyed physicians (SPs) mostly came from primary care. Prior to referral, NAFLD was rarely diagnosed, and noninvasive tests were not performed. Screening for comorbidities by SPs was incomplete and cardiovascular risk not calculated. Elastometry in combination with a serum biomarker was the most common first-line method for fibrosis staging. Liver biopsy, when performed, was often delayed by at least 1 year after diagnosis. It was, however, recommended even if noninvasive methods indicated advanced fibrosis. Frequent, biannual monitoring was conducted, including HCC surveillance in Stage 3 fibrosis. SPs rarely implemented and followed dietary and lifestyle changes themselves, and local availability of such programs was highly heterogenous. SPs favored pharmacotherapy based on mechanism of action adapted to the stage of the disease, including for early stages such as steatohepatitis with mild fibrosis. Conclusions: This international survey revealed major deficiencies and delays in referral pathways, suboptimal screening for comorbidities or managing of lifestyle modifications by SPs, and limited local availability for nonpharmacological interventions. Monitoring practices are not aligned with current guidelines.


Publication metadata

Author(s): Ratziu V, Anstee QM, Wong VW-S, Schattenberg JM, Bugianesi E, Augustin S, Gheorghe L, Zambon V, Reau N

Publication type: Article

Publication status: Published

Journal: Hepatology

Year: 2022

Volume: 76

Issue: 6

Pages: 1766-1777

Print publication date: 01/12/2022

Online publication date: 01/04/2022

Acceptance date: 28/03/2022

Date deposited: 02/06/2022

ISSN (print): 0270-9139

ISSN (electronic): 1527-3350

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1002/hep.32500

DOI: 10.1002/hep.32500

PubMed id: 35363906


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Intercept Pharmaceuticals

Share